Theranostics · Literature Radar
Lu-177 PSMA-617 / PSMA-I&T evidence — VISION, PSMAfore, dosimetry, salivary-gland and kidney safety. Curated daily from Europe PMC (PubMed + PMC + preprints) and OpenAlex — free-full-text link on each open-access paper.
Wenzel M, Le QC, Siech C, Hoeh B et al.
PurposeTo investigate cancer-control outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients receiving Lutetium-177 Prostate-Specific Membrane Antigen-617 (Lu-177-PSMA) radioligan…
Kassar M, Hu J, Rauscher I, Gomes CV et al.
Large language models show great promise for clinical decision support but generally lack medical imaging integration. Therefore, vision-language models have been proposed, but there is little evidenc…
Edouard L, Papillon L, Ferrer L, Godbert Y et al.
PurposeMetastatic castration-resistant prostate cancer (mCRPC) remains incurable despite recent therapeutic advances. [¹⁷⁷Lu]Lu-PSMA RLT (lutetium-177 labelled prostate-specific membrane antigen radio…
Kishan AU, Wilhalme H, Felix C, Enke J et al.
The phase 2 randomized LUNAR trial previously demonstrated that neoadjuvant ¹⁷⁷Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved progression-free survival (PFS) in patient…
Lin ET.
Among prostate-specific membrane antigen (PSMA)-directed radioligand therapies (RLT), ¹⁷⁷Lu-PSMA-617 is supported by two peer-reviewed phase III randomised controlled trials in metastatic castration-r…
Long H, Qiao XH, Li X, Kong XJ et al.
ObjectiveTo characterize publication growth, modality trends, and thematic evolution in prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for prostate cancer from 2015 to 2025, empha…
Hong CM, Moradi Tuchayi A, Abtahi M, Nwihim S et al.
PurposeMultiple prostate-specific membrane antigen (PSMA) PET tracers are used for patient selection in radioligand therapy (RLT). This study compared treatment response to RLT across different PSMA t…
Karimzadeh A, Fütterer C, Hansen K, Coban Ö et al.
¹⁷⁷Lu-prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is an established treatment for metastatic castration-resistant prostate cancer, though responses vary. A prognosti…
Sridharan K, Alonso-Gordoa T, Sivaramakrishnan G, Cerrillo JM et al.
IntroductionRadiotheranostics, integrating diagnostic imaging with targeted radiotherapy using molecularly matched radioactive agents, has emerged as a transformative approach in the management of pro…
Li P, Cai C, Wang Z, Song M et al.
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with ¹⁷⁷Lu-PSMA-617 improves outcomes in metastatic castration-resistant prostate cancer (mCRPC), yet a substantial subset of pat…
Noamen H, Bekkhoucha A, Bernard Tessier A, Trabelsi K et al.
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION…
Zhao R, Li M, Lv J, Zhang J et al.
Given the rapid systemic clearance and favorable kinetic profile of the novel DOTA(GA)₂-conjugated ligand [¹⁷⁷Lu]Lu-P17-087, this phase 1 study aimed to systematically evaluate the safety, pharmacokin…
Sheheryar N, Nikanpour Y, Manohar S, Childs D et al.
We conducted a study to determine the effects of ¹⁷⁷Lu-PSMA-617 treatment on renal function decline in patients with metastatic castration-resistant prostate cancer (mCRPC) shortly after treatment and…
Mahajan V, Yu L, Kollitz L, Boytim E et al.
Treatment with ¹⁷⁷Lu-PSMA-617 improves survival in some patients with metastatic castration-resistant prostate cancer, yet marked heterogeneity in treatment response underscores the need for robust bi…
Shen DH, Chen KC, Chen IA, Lee MC et al.
We report a 55-year-old man with metastatic castration-resistant prostate cancer who developed a dramatic "scintigraphic flip" after the second cycle of ¹⁷⁷Lu-PSMA therapy. Post-therapy SPECT and foll…
Osbourne J, Hofman MS, Ruderman I.
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is a novel theranostic approved for the treatment of metastatic castration-resistant prostate cancer. It has been understoo…
Yuan R, Yaniv B, Grivas P, Patnaik MM et al.
IntroductionTwo radiopharmaceuticals are approved for metastatic castration-resistant prostate cancer (mCRPC): Radium-223 and ¹⁷⁷Lu-PSMA-617. While short-term hematologic toxicity is well-studied, the…
Fersing C, Vanney J, Torchio J, Renaud SC et al.
IntroductionRadioligand Therapy (RLT) targeting Prostate-Specific Membrane Antigen (PSMA) reshapes the therapeutic landscape of metastatic castration-resistant prostate cancer. However, the rapid syst…
Mattana F, Palesandro E, Dragonetti V, Curigliano G et al.
BackgroundThe management of metastatic castration-resistant prostate cancer (mCRPC) after progression on androgen receptor pathway inhibitors (ARPI) and docetaxel presents a critical therapeutic choic…
Lee MJ, Yu L, Zorko N, Dehm S et al.
Background: 177Lu-PSMA-617 radioligand treatment represents a major advancement in the management of metastatic castration-resistant prostate cancer (mCRPC), but key questions remain about tumor-cell …
Adib E, Lee E, Chen YH, Menon K et al.
Metastasis-directed external beam radiation therapy (EBRT) delivered for limited-volume disease, integrated with systemic radioligand therapy, may improve long-term disease control across the spectrum…
Ananda FD, Hardiansyah D, Ritawidya R, Beer AJ et al.
This study evaluates the feasibility of Single-Time-Point (STP) renal Time-Integrated Activity (TIA) estimation using Population-Based Model Selection (PBMS) and Nonlinear Mixed-Effects Modelling (NLM…
Sen Wang, Shoujun Tang, ShengJie Tang, Chun Wang et al.
Radioligand therapy (RLT) delivers therapeutic radionuclides to tumor-associated targets through specific targeting ligands and has demonstrated substantial clinical value in malignancies such as pros…
Wang Z, Fukushima H, Yajima S, Fujiwara M et al.
Abstract Objective: To evaluate adverse-event incidence and uncertainty with lutetium-177 prostate-specific membrane antigen (PSMA) radioligand therapy across clinically distinct treatment settings. M…
Aggarwal P, Sood A, Satapathy S, Goyal S et al.
Background[177Lu]Lu-PSMA-617 has been an approved treatment modality for metastatic castration-resistant prostate cancer (mCRPC). Recent studies have shown PSMA upregulation following enzalutamide, wh…
Ells Z, Hempel L, Ells J, Wu M et al.
IntroductionAdministration activities of 177Lu-PSMA were chosen cautiously in the treatment of advanced prostate cancer. The primary aim was to investigate the association between increased injected a…
Wahl RL, Dewaraja YK.
Radiopharmaceutical therapy (RPT) is growing in clinical importance and utilization. First-generation RPTs such as 131I-tositumomab (Bexxar) radioimmunotherapy of lymphoma used simplified whole-body d…
Hadaschik B, Sartor O.
Theranostics, particularly PSMA-targeted imaging and radiopharmaceutical therapy, is rapidly transforming the field of urooncology. This article reviews the clinical integration of PSMA PET/CT in diag…
Giunta EF, Marini I, Grassi I, Nicolini S et al.
177Lu-PSMA is currently approved for metastatic castration-resistant prostate cancer (mCRPC). However, only a subset of eligible patients derives a meaningful clinical benefit from treatment. To date,…
Tolmeijer SH, Kwan EM, Gafita A, Hamid AA et al.
The PRINCE trial showed the clinical activity for 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration-resistant prostate cancer. To refine patient selection and improve response…
Usmani S, Al Balushi A, Al Saadi S, Jain A et al.
Objective¹⁷⁷Lu-PSMA-617 radioligand therapy (RLT) is an established treatment for metastatic castration-resistant prostate cancer (mCRPC). Its predominant renal clearance pathway raises concerns about…
Thomas Büttner, Mike Wenzel, Philipp Mandel, Paul Schmitt et al.
PURPOSE: Lu]Lu-PSMA-617 is a standard-of-care therapy for metastatic castration-resistant prostate cancer (mCRPC). Given the heterogeneous clinical responses, accessible prognostic tools are needed. W…
Weirong Shi, Limin Zhang, Xinyue Feng, Jiayu Liu et al.
Lutetium-177 ( 177 Lu)–based Radioligand Therapy (RLT) has emerged as an important modality in precision oncology, with demonstrated clinical benefit in selected malignancies. Its clinical relevance i…
Wang Ye, Kunhao Liu, Leijie Wang, Linjie Wu et al.
Objective Recurrence after radical prostatectomy (RP) remains a major clinical challenge in prostate cancer and is characterized by substantial heterogeneity in recurrence patterns. This review aimed …
Odibo A.
Lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617; Pluvicto, Novartis) is a small-molecule, prostate-specific membrane antigen (PSMA)-targeted radioligand that has redefined the treatment of metas…
Kashyap R, Buteau JP, Papa N, Ayati N et al.
We analyzed the prognostic value of an interim [18F]FDG PET/CT performed after cycle 3 of [177Lu]Lu-PSMA-617 ([177Lu]Lu-PSMA) for patients undergoing therapy for metastatic castration-resistant prosta…
Hasenauer N, Probst C, Schloetelburg W, Jedamzik T et al.
In this study, we compared clinical outcomes and safety profiles of radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA I&T in patients with metastatic castration-resistant prostate…
Amghar M, Hielscher T, Rausch T, Özgür H et al.
BackgroundProstate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT) demonstrates clinical efficacy in metastatic castration-resistant prostate cancer (mCRPC), yet robust biomarkers fo…
Tavakoli M, Pirayesh E, Khoshbakht S, Javan Shayani P et al.
PurposeNeuroendocrine differentiation is a recognized phenotypic change in advanced prostate cancer. Neuroendocrine-like cells may lack androgen receptor or prostate-specific membrane antigen expressi…
Gokce Belge Bilgin, Cem Bilgin, MD Ann T. Packard, Miller MD et al.
Purpose Radioligand therapy (RLT) with [ 177 Lu] Lu-PSMA-617 has shown significant benefits in metastatic castration-resistant prostate cancer (mCRPC), including prolonged overall survival (OS) and pr…
Mallareddy Banala, Shabbir Ezuddin, Mark Foley, Russ Kuker
Artificial intelligence (AI) has been studied across radiopharmaceutical therapy (RPT); however, evidence for treatment-changing use remains limited. We conducted a structured narrative review with de…
D. Coll Segarra, S. Arias Soriano, S.V. Tipnis, J.A. Nye
INTRODUCTION: A practical approach is presented to reliably detect and quantify the long-lived contaminant 177m Lu commonly found in 177 Lu-based therapeutics. OBJECTIVE: The objective of this work wa…
Winter RC, Bauder-Wüst U, Schäfer M, Remde Y et al.
Metastatic cancer remains a major challenge, demanding more effective and biologically informed therapeutic strategies. Targeted Radionuclide Therapy (TRT) holds significant promise, but its optimizat…
Aurilio M, Maisto C, Morisco A, Esposito A et al.
Radioligand therapy (RLT) with [¹⁷⁷Lu]-Lu-radiolabeled pharmaceuticals targeting PSMA is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC), with th…
Alexandra Litvinenko, Hélène Koch, Gianluca Corsanici, Giulia Battistini et al.
Nuclear theranostics has transitioned from proof-of-concept to clinical practice with the regulatory approval of SSTR- and PSMA-targeted radioligand therapies. However, therapeutic outcomes remain con…
Jialiang Deng, Guoxiong Ma, Weijin Chen, Songhao Wen et al.
[ 177 Lu]Lu-PSMA radioligand therapy (LuPSMA RLT) has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), yet clinically meaningful response heterogeneity pers…
Förner L, Schmutz M, Claus R, Lapa C et al.
Longitudinal oncologic imaging poses a tracking challenge because lesions can split, merge, or transiently disappear, violating one-to-one correspondence assumptions. We propose spatio-temporal lesion…
Matthew Benger, Georgios Krokos, Karan Daga, Alan J. Wright et al.
Abstract Prostate-specific membrane antigen (PSMA) is upregulated in high-grade glioma (HGG). This study aimed, firstly, to establish dosimetry for the radionuclide [68Ga]-PSMA-11 in HGG patients; sec…
Narendra Rathod
The application of artificial intelligence (AI) in positron emission tomography (PET)-based internal dosimetry in radiopharmaceutical therapy (RPT), with an emphasis on the paradigm shift from resourc…
Cerci JJ, Fanti S, Herrmann K, Rodrigues DF et al.
Real-world disparities in access to PSMA-targeted theranostics are poorly characterized. We compared waiting times for PSMA PET/CT and 177Lu-PSMA therapy between centers in Brazil and Europe. Methods:…
Christopher Montemagno, Benjamín Serrano, Benoît Paulmier
Theranostics occupies a unique position in oncology because the same molecular target simultaneously enables disease visualization and therapeutic delivery. Unlike most anticancer strategies, where bi…
E Novruzov, Eduards Mamlins, Joseph Kabunda, Jens Cardinale et al.
Abstract Background PSMA-PET/CT became an important means for prostate cancer management. The high-resolution and signal-to-noise ratio of PET is mandatory in primary staging or biochemical relapse th…
Scharf Z, Muniz M, Tchitchkan E, Rami A et al.
[177Lu]Lu-PSMA-617 improves survival and quality of life in men with metastatic castration-resistant prostate cancer but requires substantial healthcare involvement. Our analysis evaluated the time to…
Adrien Holzgreve, Sophie C. Siegmund, Liam Widjaja, Rudolf A. Werner
management of patients with advanced prostate cancer, firmly anchored in clinical guidelines [8].This article provides an update on established PSMA theranostics using beta-emitting ligands, based on …
Krieger K, Mapanao AK, Bolcaen J, Kegler K et al.
PurposeThe successful preclinical efficacy studies prompted a Phase I clinical trial to investigate [161Tb]Tb-SibuDAB. Deeper insight into potential undesired effects on normal tissues and organs rema…
Bekkhoucha A, Zaragori T, Olivier P, Claudin M et al.
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 has reshaped the management of metastatic castration-resistant prostate cancer (mCRPC). This stud…
Iravani A, Gulati R, Miyaoka R, Reiger AC et al.
[177Lu]Lu-PSMA-617 is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC); however, response rates vary significantly, particularly among patients with low prostate-specifi…
Park HL, Kersting D, Bergstrom CP, Khaki AR et al.
This article evaluates whether early same-day posttherapy whole-body SPECT/CT assessed using visual RECIP 1.0 is associated with overall survival (OS) in patients with metastatic castration-resistant …
Mubarika M, Maaz M, Muhammad A, Emmama S et al.
Background and objectiveLutetium-177-PSMA radioligand therapy ([177Lu] Lu-PSMA) is an emerging targeted treatment for metastatic castration-resistant prostate cancer (mCRPC). We evaluated the comparat…
Nault B, Garcia D, Cameron H, Revel A et al.
The TheraP trial compared cabazitaxel to Lutetium-177-labeled PSMA-617 (Lu-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) following docetaxel and an androgen receptor pathway inhibit…
Showing the 60 most recent of 164 papers in this topic.Browse every paper →
Request brochure
Tell us who you are and we’ll send the full product brochure to your institutional email after a quick review. We respond within one working day (Mon–Fri, 9:30–18:30 IST).
A Saxsons sales engineer will review your request and send the brochure to your institutional email within one working day. You may receive a verification call before processing.
